摘要
本文报告了经静脉滴注(IVD)、支气管动脉灌注(BAI)和经支气管动脉及肺动脉双重动脉灌注(DAI)三种给药途径治疗中晚期非小细胞型肺癌(NSCLC)132例,近期有效率分别达41.6%、73.1%和80%,中位生存期达7.6、11和11.5个月,差异有显著性.本文认为,卡铂和足叶乙甙是治疗非小细胞肺癌的较好化疗方案.采用BAI可使高浓度化疗药物作用于肿瘤局部,缩瘤率高,提高了手术切除率.肺为双重动脉供血,支气管动脉和肺动脉相辅相成,采用DAI能弥补单纯BAI的某些不足,提高疗效,也可减少和避免单纯BAI的某些副作用.
In treating 132 cases of NSCLC in middle & late stage,Three ways of drug administration had been reported as follows:Intravenous drop (IVD)Bronchial artery infusion (BAI)&Dual artery infusion(DAI). The recent effective rate attained 41.9%,73. 1% & 80% with mean survival span 7.6 ,11 & 11.5 months respectively. The author considers that the combination of Carboplatin & Etopside is a better plan to treat NSCILC. The hige concentration of chemical drugs directly act on the local tumor by applying BAI,with high shrinking rate of tumor and increased resectionrate. Because of double blood supply of lung by bronchial & pulmonary arteries DAI will supplement certain defects of simple BAI,increase therapeutic deffect and (as well as )reduce &avoid certain side effdct of BAI only.
